Award

Pilot trial of SGLT2 inhibitor dapagliflozin for stage Ia lung adenocarcinoma

Description: Lung cancer is the number one cause of cancer-related death, and lung adenocarcinoma (LUAD) is the most frequent type. Lung cancer screening in heavy smokers allows the detection of early lesions that can be removed surgically. However, not all patients can receive surgery. In many cases, there are multiple lesions that cannot all be removed surgically. Even if an early LUAD is removed, the same patient has increased risk of future lung cancer. There is the need for a safe and tolerable medical treatment that can block the progression of early LUAD lesions and reduce the risk of future LUAD. We showed that a class of drugs used for diabetes, the SGLT2 inhibitors (SGLT2is), delay LUAD development in pre-clinical. Since SGLT2is are used for diabetes, there is evidence that diabetic patients taking SGLT2is have better lung cancer outcomes than diabetic patients treated with other drugs. However, the safety and efficacy of SGLT2is in LUAD have not been established. We propose a pilot clinical trial in patients with early LUAD identified by screening and referred for surgery. This is a single-arm study in which 48 patients with available pre-surgery biopsy tissue will receive 30 days of dapagliflozin, an SGLT2i, followed by surgery. This will allow us to assess the safety and tolerability of dapagliflozin for patients with early-stage LUAD, and to confirm that dapagliflozin has a biological effect on human LUAD. The biological effect will be measured by comparing the biopsy sample before the treatment and the surgical sample collected at the end of the trial, as well as blood and urine samples collected before and after the treatment to measure various biomarkers. This study will provide the necessary data to justify future, larger chemoprevention studies of SGLT2i for early LUAD.
Amount: $1,213,000
Start date: 2025-07-01
Field: Medicine
Funded outputs count: 0
Funder award ID: g9wttj
OpenAlex ID: G1296855650